Adams Street Partners LLC Acquires New Shares in Palvella Therapeutics (NASDAQ:PVLA)

Adams Street Partners LLC purchased a new stake in Palvella Therapeutics (NASDAQ:PVLA - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 409,666 shares of the company's stock, valued at approximately $4,916,000. Palvella Therapeutics accounts for about 4.4% of Adams Street Partners LLC's investment portfolio, making the stock its 5th largest position. Adams Street Partners LLC owned approximately 3.65% of Palvella Therapeutics as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Samsara BioCapital LLC bought a new position in shares of Palvella Therapeutics during the 4th quarter worth about $8,154,000. Nantahala Capital Management LLC bought a new position in Palvella Therapeutics during the fourth quarter worth about $3,001,000. Blue Owl Capital Holdings LP acquired a new stake in Palvella Therapeutics during the fourth quarter valued at approximately $3,001,000. Renaissance Technologies LLC bought a new stake in shares of Palvella Therapeutics in the 4th quarter valued at approximately $256,000. Finally, ADAR1 Capital Management LLC bought a new position in shares of Palvella Therapeutics during the 4th quarter worth approximately $1,736,000. 40.11% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Palvella Therapeutics

In other news, Director George M. Jenkins acquired 2,500 shares of the stock in a transaction that occurred on Wednesday, April 9th. The stock was purchased at an average cost of $20.13 per share, for a total transaction of $50,325.00. Following the completion of the transaction, the director now directly owns 183,171 shares in the company, valued at $3,687,232.23. This trade represents a 1.38 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. 6.39% of the stock is currently owned by corporate insiders.

Palvella Therapeutics Trading Up 1.5 %

Shares of NASDAQ PVLA traded up $0.37 during trading on Friday, reaching $24.46. The company had a trading volume of 51,579 shares, compared to its average volume of 71,726. The business's 50 day moving average is $24.56. Palvella Therapeutics has a 52 week low of $6.20 and a 52 week high of $29.27. The stock has a market cap of $269.52 million, a PE ratio of -2.02 and a beta of 0.10.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Scotiabank initiated coverage on Palvella Therapeutics in a research note on Friday, March 7th. They set a "sector outperform" rating and a $50.00 price objective for the company. Canaccord Genuity Group reiterated a "buy" rating and set a $39.00 target price on shares of Palvella Therapeutics in a research report on Wednesday, February 26th. Jones Trading assumed coverage on shares of Palvella Therapeutics in a research report on Tuesday, March 25th. They issued a "buy" rating and a $45.00 price target on the stock. Chardan Capital began coverage on shares of Palvella Therapeutics in a report on Wednesday, April 9th. They set a "buy" rating and a $50.00 price objective for the company. Finally, HC Wainwright reiterated a "buy" rating and issued a $38.00 target price on shares of Palvella Therapeutics in a research note on Wednesday. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $44.43.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.